Publications
Detailed Information
Cell cycle arrest induced by engagement of B7-H4 on Epstein-Barr virus-positive B-cell lymphoma cell lines
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Ga Bin | - |
dc.contributor.author | Song, Hyunkeun | - |
dc.contributor.author | Kim, Yeong-Seok | - |
dc.contributor.author | Sung, Minjung | - |
dc.contributor.author | Lee, Hyun-Kyung | - |
dc.contributor.author | Kim, Daejin | - |
dc.contributor.author | Hur, Dae Y. | - |
dc.contributor.author | Lee, Wang J. | - |
dc.contributor.author | Cho, Dae-Ho | - |
dc.contributor.author | Ryu, Jeoung W. | - |
dc.date.accessioned | 2012-07-10T00:32:43Z | - |
dc.date.available | 2012-07-10T00:32:43Z | - |
dc.date.issued | 2009-11 | - |
dc.identifier.citation | IMMUNOLOGY; Vol.128(3); 360-368 | ko_KR |
dc.identifier.issn | 0019-2805 | - |
dc.identifier.uri | https://hdl.handle.net/10371/78674 | - |
dc.description.abstract | B7-H4 is a recently discovered B7 family member that has inhibitory effects on T-cell immunity. However, the reverse signalling mechanism of the B7-H4-expressing cells remains unclear. Previous work has shown that B7-H4 expression was enhanced on B cells following Epstein-Barr virus (EBV) infection, and engagement of cell-surface-expressed B7-H4 induces cell death of EBV-transformed B cells. Here we found that B7-H4 was constitutively expressed on EBV-positive lymphoma cells, Raji and IM-9 cells, but was not expressed on EBV-negative lymphoma cells (Ramos). Engagement of B7-H4 significantly reduced cell growth of Raji and IM-9 cells and resulted in cell cycle arrest at G0-G1 phase in a dose- and time-dependent manner. To clarify the mechanism of cell cycle arrest via activation of B7-H4, cell cycle regulatory factors were examined by reverse transcription-polymerase chain reaction and immunoblotting. We found that B7-H4 triggered down-regulation of CDK4/6 and up-regulation of p21 expression at both protein and RNA levels. Furthermore, CDK2 and cyclin E/D expression was down-regulated by B7-H4 triggering. Additionally, the down-regulation of phospho-AKT and phospho-cyclin E were clearly detected in B7-H4-activated Raji cells, but the phosphorylation of p53 was constitutively maintained. These results indicate that B7-H4-mediated signalling on EBV-positive B-cell lymphoma cells modulates the cell cycle through down-regulation of the AKT pathway. Consequently, B7-H4 may be a new potential target for use in EBV-positive lymphoma therapy. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | WILEY-BLACKWELL PUBLISHING, INC | ko_KR |
dc.subject | apoptosis | ko_KR |
dc.subject | Epstein-Barr virus | ko_KR |
dc.subject | costimulation | ko_KR |
dc.subject | cell cycle | ko_KR |
dc.subject | cancer | ko_KR |
dc.subject | B7-H4 | ko_KR |
dc.subject | B cells | ko_KR |
dc.title | Cell cycle arrest induced by engagement of B7-H4 on Epstein-Barr virus-positive B-cell lymphoma cell lines | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 박가빈 | - |
dc.contributor.AlternativeAuthor | 송현근 | - |
dc.contributor.AlternativeAuthor | 김영석 | - |
dc.contributor.AlternativeAuthor | 성민정 | - |
dc.contributor.AlternativeAuthor | 이현경 | - |
dc.contributor.AlternativeAuthor | 조대호 | - |
dc.contributor.AlternativeAuthor | 김대진 | - |
dc.contributor.AlternativeAuthor | 이왕재 | - |
dc.contributor.AlternativeAuthor | 허대영 | - |
dc.identifier.doi | 10.1111/j.1365-2567.2009.03111.x | - |
dc.citation.journaltitle | IMMUNOLOGY | - |
dc.description.citedreference | Yin Y, 2008, ONCOGENE, V27, P5443, DOI 10.1038/onc.2008.241 | - |
dc.description.citedreference | Song H, 2008, CANCER LETT, V266, P227, DOI 10.1016/j.canlet.2008.02.067 | - |
dc.description.citedreference | Besson A, 2008, DEV CELL, V14, P159, DOI 10.1016/j.devce1.2008.01.013 | - |
dc.description.citedreference | Simon I, 2007, GYNECOL ONCOL, V106, P112, DOI 10.1016/j.ygyno.2007.03.007 | - |
dc.description.citedreference | Flies DB, 2007, J IMMUNOTHER, V30, P251 | - |
dc.description.citedreference | Maddika S, 2007, DRUG RESIST UPDATE, V10, P13, DOI 10.1016/j.drup.2007.01.003 | - |
dc.description.citedreference | Sengupta S, 2006, CANCER RES, V66, P7999, DOI 10.1158/0008-5472.CAN-05-4399 | - |
dc.description.citedreference | Wikman H, 2006, EXPERT REV ANTICANC, V6, P515, DOI 10.1586/14737140.6.4.515 | - |
dc.description.citedreference | Simon I, 2006, CANCER RES, V66, P1570, DOI 10.1158/0008-5472.CAN-04-3550 | - |
dc.description.citedreference | Georgakis GV, 2006, BRIT J HAEMATOL, V132, P503, DOI 10.1111/j.1365-2141.2005.05881.x | - |
dc.description.citedreference | Tringler B, 2006, GYNECOL ONCOL, V100, P44, DOI 10.1016/j.ygyno.2005.08.060 | - |
dc.description.citedreference | Kaldis P, 2005, CELL CYCLE, V4, P1491 | - |
dc.description.citedreference | Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619 | - |
dc.description.citedreference | Tringler B, 2005, CLIN CANCER RES, V11, P1842 | - |
dc.description.citedreference | Kozar K, 2005, CELL CYCLE, V4, P388 | - |
dc.description.citedreference | Baker GL, 2005, CELL CYCLE, V4, P330 | - |
dc.description.citedreference | Greenwald RJ, 2005, ANNU REV IMMUNOL, V23, P515, DOI 10.1146/annurev.immunol.23.021704.115611 | - |
dc.description.citedreference | Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452 | - |
dc.description.citedreference | Kuppers R, 2003, NAT REV IMMUNOL, V3, P801, DOI 10.1038/nri1201 | - |
dc.description.citedreference | Sica GL, 2003, IMMUNITY, V18, P849 | - |
dc.description.citedreference | Appleman LJ, 2003, IMMUNOL REV, V192, P161 | - |
dc.description.citedreference | LIANG J, 2003, CELL CYCLE, V2, P339 | - |
dc.description.citedreference | Salek-Ardakani S, 2002, VIROLOGY, V304, P342, DOI 10.1006/viro.2002.1716 | - |
dc.description.citedreference | Pene F, 2002, ONCOGENE, V21, P6587, DOI 10.1038/sj.onc.1205923 | - |
dc.description.citedreference | Suvas S, 2002, J BIOL CHEM, V277, P7766, DOI 10.1074/jbc.M105902200 | - |
dc.description.citedreference | Mayo LD, 2002, J BIOL CHEM, V277, P5484, DOI 10.1074/jbc.M108302200 | - |
dc.description.citedreference | Rickinson A, 2002, VIRUS RES, V82, P109 | - |
dc.description.citedreference | Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598 | - |
dc.description.citedreference | Tu YP, 2000, CANCER RES, V60, P6763 | - |
dc.description.citedreference | Chakravarthy MV, 2000, J BIOL CHEM, V275, P35942 | - |
dc.description.citedreference | Sherr CJ, 1999, GENE DEV, V13, P1501 | - |
dc.description.citedreference | Muller A, 1998, EUR J IMMUNOL, V28, P3488 | - |
dc.description.citedreference | Maeurer MJ, 1996, CLIN CANCER RES, V2, P641 | - |
dc.description.citedreference | AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493 | - |
dc.description.citedreference | FREEMAN GJ, 1995, IMMUNITY, V2, P523 | - |
dc.description.tc | 3 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.